Briefing
NCCN 2026 discussion adds niraparib plus abiraterone for BRCA2-mutated metastatic hormone-sensitive prostate cancer
At the NCCN 2026 Annual Conference, faculty reported that ADT plus niraparib and abiraterone is listed for BRCA2-mutated metastatic androgen-pathway-sensitive prostate cancer, as useful in certain circumstances for high-volume disease and as a category 2B option for low-volume disease.